tiprankstipranks
Advertisement
Advertisement

GRCE Stock Latest News

Largest borrow rate increases among liquid names
The FlyLargest borrow rate increases among liquid names
5d ago
PS
KDK
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
6d ago
BUD
KDK
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
PremiumCompany Announcements
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
20d ago
8K
GRCE
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
PremiumThe Fly
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum
23d ago
GRCE
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
PremiumThe Fly
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen
23d ago
GRCE
Grace Therapeutics: Buy Rating Maintained as Addressable CMC Setback Delays but Does Not Derail GTx‑104 Value Thesis
PremiumRatingsGrace Therapeutics: Buy Rating Maintained as Addressable CMC Setback Delays but Does Not Derail GTx‑104 Value Thesis
24d ago
GRCE
Grace Therapeutics Receives FDA Complete Response for GTx-104
Premium
Company Announcements
Grace Therapeutics Receives FDA Complete Response for GTx-104
24d ago
8K
GRCE
Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104
Premium
The Fly
Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104
24d ago
GRCE
Grace Therapeutics, Inc trading resumes
PremiumThe Fly
Grace Therapeutics, Inc trading resumes
24d ago
GRCE
Grace Therapeutics issued Complete Response Letter from FDA
PremiumThe Fly
Grace Therapeutics issued Complete Response Letter from FDA
24d ago
GRCE
Grace Therapeutics, Inc trading halted, news pending
PremiumThe Fly
Grace Therapeutics, Inc trading halted, news pending
24d ago
GRCE
Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year
PremiumThe Fly
Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year
3M ago
GRCE
Ten new option listings and two option delistings on January 22nd
PremiumThe FlyTen new option listings and two option delistings on January 22nd
4M ago
AVR
INR
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
Premium
Company Announcements
Grace Therapeutics Enhances Executive Severance and Change‑in‑Control Terms
4M ago
8K
GRCE
Grace Therapeutics Reports Q2 2026 Results and FDA Progress
Premium
Company Announcements
Grace Therapeutics Reports Q2 2026 Results and FDA Progress
6M ago
GRCE
Grace Therapeutics Announces Q2 2026 Financial Results
PremiumCompany Announcements
Grace Therapeutics Announces Q2 2026 Financial Results
6M ago
8K
GRCE
Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year
PremiumThe Fly
Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year
6M ago
GRCE
Grace Therapeutics Secures $4M Through Warrant Exercise
PremiumCompany Announcements
Grace Therapeutics Secures $4M Through Warrant Exercise
7M ago
8K
GRCE
Grace Therapeutics secures $4M through common warrant exercises
PremiumThe Fly
Grace Therapeutics secures $4M through common warrant exercises
7M ago
GRCE
Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial
PremiumThe FlyGrace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial
8M ago
GRCE
Grace Therapeutics Secures New Patent for GTx-104
Premium
Company Announcements
Grace Therapeutics Secures New Patent for GTx-104
8M ago
8K
GRCE
Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104
Premium
The Fly
Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104
8M ago
GRCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >